French AFU Cancer Committee Guidelines – Update 2026–2028: Kidney cancer - 20/11/26
, Zine-Eddine Khene a, c, Gaëlle Margue a, d, Laurence Albiges a, e, Philippe Barthelemy a, f, Jean-Christophe Bernhard a, d, Jean-Michel Correas a, g, Stéphane De Vergie a, h, Nicolas Doumerc a, i, Matthieu Ferragu a, b, Alexandre Ingels a, j, Idir Ouzaïd a, k, Caroline Pettenati a, l, Nathalie Rioux-Leclercq a, m, Olivier Chapet a, n, Thibaut Waeckel a, o, Romain Boissier a, p, Morgan Rourpret a, qAbstract |
Objective |
To update recommendations for the management of kidney cancer.
Methods |
A systematic review of the literature published between 2014 and 2026 was performed to identify relevant evidence on diagnosis, classification, treatment, and follow-up. Recommendations were graded as strong or weak.
Results |
Contrast-enhanced thoraco-abdominal CT remains the reference for diagnosis and staging, while PET/CT is not routinely indicated. Percutaneous biopsy is recommended when it may influence therapeutic decision-making and reduce unnecessary surgery for benign tumors. Tumors are classified according to the 2017 pTNM classification (revised in 2025), the 2022 WHO classification, and ISUP grade; metastatic disease is stratified by IMDC risk group. For T1 tumors, minimally invasive robot-assisted partial nephrectomy is the reference surgical treatment. Active surveillance should be offered for masses ≤ 2 cm regardless of age and may be considered for selected tumors up to 4 cm. Ablative therapies and stereotactic radiotherapy are alternatives for patients unsuitable for surgery. Radical nephrectomy remains the standard for locally advanced disease, and adjuvant pembrolizumab is recommended for patients at high risk of recurrence. Immediate cytoreductive nephrectomy is not recommended in poor-risk metastatic disease. First-line treatment of metastatic clear cell RCC relies on immune checkpoint inhibitor-based combinations according to IMDC risk. Clinical trial enrollment should be prioritized after progression on adjuvant pembrolizumab and in later treatment lines. Patients with non-clear cell RCC should undergo expert multidisciplinary review, with priority given to clinical trials. Appropriate use of healthcare resources and environmental sustainability are integrated throughout the recommendations.
Conclusions |
These updated recommendations incorporate recent advances in diagnosis, surgery, systemic therapy, and disease monitoring, providing a contemporary evidence-based framework for the management of kidney cancer across disease stages.
Le texte complet de cet article est disponible en PDF.Keywords : Renal cell carcinoma, Clinical practice guidelines, Partial nephrectomy, Active surveillance, Systemic therapy
Plan
Vol 36 - N° 11
Article 103185- janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
